Drug Profile
ADG 106
Alternative Names: ADG-106Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Adagene
- Developer Adagene; Merck & Co; National University Hospital (Singapore)
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II HER2 negative breast cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)